1. Home
  2. GSIT vs TRDA Comparison

GSIT vs TRDA Comparison

Compare GSIT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GSI Technology

GSIT

GSI Technology

HOLD

Current Price

$7.54

Market Cap

280.0M

Sector

Technology

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.05

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIT
TRDA
Founded
1995
2016
Country
United States
United States
Employees
125
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.0M
274.5M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
GSIT
TRDA
Price
$7.54
$7.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
1.7M
262.3K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,122,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
22.44
N/A
52 Week Low
$2.82
$4.93
52 Week High
$18.14
$16.45

Technical Indicators

Market Signals
Indicator
GSIT
TRDA
Relative Strength Index (RSI) 41.83 46.90
Support Level $6.99 $5.75
Resistance Level $8.99 $7.54
Average True Range (ATR) 0.84 0.46
MACD -0.25 0.27
Stochastic Oscillator 9.73 89.27

Price Performance

Historical Comparison
GSIT
TRDA

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: